Is this a better healthcare buy than AstraZeneca plc after today’s update?

Will this healthcare stock keep beating AstraZeneca plc (LON: AZN)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

One of the UK’s leading providers of veterinary services CVS Group (LSE: CVS) has released a set of upbeat full-year results that suggest now could be the right time to buy it. But is it a superior buy to healthcare sector peer AstraZeneca (LSE: AZN)?

CVS’s sales increased by 30.4% versus the prior year. They were aided by like-for-like (LFL) sales growth of 4.8% that benefitted from increased investment in the company’s services, staff and customer services. Rising sales boosted adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) by 42.5%, which made 2016 a record year in terms of sales and profitability for CVS.

In 2016 CVS acquired 67 surgeries, three crematoria, the VetShare buying group and the VETisco instrumentation business. Together, those businesses are due to deliver sales in excess of £50m per annum and the acquisitions (plus three further surgery acquisitions post-year-end) mean that CVS now operates 363 surgeries. This provides it with a size and scale advantage over a number of its smaller peers that could help it improve its margins over the medium term.

Should you invest £1,000 in AstraZeneca right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if AstraZeneca made the list?

See the 6 stocks

Since the start of the year, CVS’s share price has risen by 13%. This is ahead of the 11% share price gain made by AstraZeneca in 2016. CVS’s growth potential is high thanks to an aggressive acquisition strategy as well as a growing referrals business. It also enjoys a rising level of customer loyalty thanks in part to its Healthy Pet Club, where membership numbers increased by 18% in the last financial year.

CVS is forecast to increase its bottom line by 15% in the current financial year. This puts it on a price-to-earnings growth (PEG) ratio of just 1.7, which indicates that its shares offer further upside. That rate of growth is well ahead of AstraZeneca’s expected decline in earnings of 2% this year and 3% next year.

Long-term pick?

AstraZeneca is struggling to overcome the losses of patents on key drugs. It will take time for the company to return to positive bottom line growth, but it’s on track to do so over the medium term. This is due to its major acquisition programme that has already dramatically improved the company’s treatment pipeline and should positively catalyse its future earnings.

Therefore, in the long run AstraZeneca could prove to be a better growth play than CVS. It offers greater scale and financial firepower to develop its growth strategy than is the case for CVS. Furthermore, AstraZeneca has a lower risk profile due to its greater geographic diversity, stronger balance sheet and more diversified income stream. Its price-to-earnings (P/E) ratio of 16.1 is also lower than CVS’s P/E ratio of 25.1, which indicates that it offers a wider margin of safety.

While CVS is a sound buy, AstraZeneca has a superior risk/reward ratio. This makes it the better buy of the two stocks for long-term investors.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

One English pound placed on a graph to represent an economic down turn
Investing Articles

Here are the latest forecast dividend yields for Sainsbury’s and Tesco shares

Our writer takes a look at the dividend yields of the UK's two leading supermarkets to help him decide which…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing Articles

Should I buy Palantir stock before 4 August?

Our writer is wondering if it's time for him to add Palantir stock to his portfolio, just in case it…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Dividend Shares

Here’s how much passive income an investor could make from a £50k portfolio

Jon Smith explores different levels of risk tolerance and provides an indication of the passive income that could be generated…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

How I’m positioning my ISA and SIPP for the AI revolution

Artificial intelligence is almost certainly going to transform multiple industries. Ben McPoland explains his strategy for his ISA and SIPP.

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

Just what will it take to turn around the plummeting Croda share price?

Andrew Mackie examines the likelihood of a turnaround in the Croda share price, which is down 8% after another disappointing…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

2 high-yield dividend stocks to consider buying in August

The FTSE 100 is up near an all-time high now, at over 9,000 points. But there are still some UK…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

This 9.3% yield’s unbeatable! But is it really the FTSE 100’s best dividend stock?

Harvey Jones is blown away by the amount of income this FTSE 100 dividend stock is now offering investors. But…

Read more »

Abstract 3d arrows with rocket
Investing Articles

Up 65% since April, is this ex-penny share ready to rocket higher?

Ben McPoland looks at Virgin Galactic (NYSE:SPCE), a former penny share that has exploded skywards in the past three months.…

Read more »